Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
68.47 (1y: +61%)
Market Cap 3.39 B P/E(ttm) 12.10
Enterprise Value 2.99 B P/B 3.20
UTHR- NAS (USA)
United Therapeutics Corporation
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$68.47
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt 1.743
UTHR's Cash to Debt is ranked lower than
71% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. UTHR: 1.743 )
UTHR' s 10-Year Cash to Debt Range
Min: 0.85   Max: 5455.83
Current: 1.74
0.85
5455.83
Equity to Asset 0.656
UTHR's Equity to Asset is ranked higher than
59% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. UTHR: 0.656 )
UTHR' s 10-Year Equity to Asset Range
Min: 0.41   Max: 0.9
Current: 0.66
0.41
0.9
Interest Coverage 33.2
UTHR's Interest Coverage is ranked lower than
60% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. UTHR: 33.2 )
UTHR' s 10-Year Interest Coverage Range
Min: 3   Max: No Debt
Current: 33.2
F-Score: 7
Z-Score: 6.09
M-Score: -3.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 46.00
UTHR's Operating margin (%) is ranked higher than
92% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. UTHR: 46.00 )
UTHR' s 10-Year Operating margin (%) Range
Min: -8850   Max: 46
Current: 46
-8850
46
Net-margin (%) 33.2
UTHR's Net-margin (%) is ranked higher than
93% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. UTHR: 33.2 )
UTHR' s 10-Year Net-margin (%) Range
Min: -8375   Max: 56.1
Current: 33.2
-8375
56.1
ROE (%) 28.1
UTHR's ROE (%) is ranked higher than
94% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. UTHR: 28.1 )
UTHR' s 10-Year ROE (%) Range
Min: -62.5   Max: 36.1
Current: 28.1
-62.5
36.1
ROA (%) 18.7
UTHR's ROA (%) is ranked higher than
93% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. UTHR: 18.7 )
UTHR' s 10-Year ROA (%) Range
Min: -55.9   Max: 22.3
Current: 18.7
-55.9
22.3
ROC (Joel Greenblatt) (%) 90.40
UTHR's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -0.20 vs. UTHR: 90.40 )
UTHR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8850   Max: 101.7
Current: 90.4
-8850
101.7
Revenue Growth (%) 27.1
UTHR's Revenue Growth (%) is ranked higher than
89% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. UTHR: 27.1 )
UTHR' s 10-Year Revenue Growth (%) Range
Min: 18.8   Max: 192.3
Current: 27.1
18.8
192.3
EBITDA Growth (%) 88.3
UTHR's EBITDA Growth (%) is ranked lower than
74% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -11.35 vs. UTHR: 88.3 )
UTHR' s 10-Year EBITDA Growth (%) Range
Min: -43.2   Max: 109.1
Current: 88.3
-43.2
109.1
EPS Growth (%) 101
UTHR's EPS Growth (%) is ranked lower than
78% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. UTHR: 101 )
UTHR' s 10-Year EPS Growth (%) Range
Min: -41.2   Max: 101
Current: 101
-41.2
101
ยป UTHR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

UTHR Guru Trades in Q2 2012

HOTCHKIS & WILEY 72,000 sh (New)
Joel Greenblatt 332,744 sh (+101.59%)
Vanguard Health Care Fund 1,787,000 sh (unchged)
Richard Perry Sold Out
Jim Simons 414,478 sh (-34.02%)
Steven Cohen 20,873 sh (-45.07%)
Paul Tudor Jones 6,800 sh (-51.77%)
» More
Q3 2012

UTHR Guru Trades in Q3 2012

John Hussman 500,000 sh (New)
HOTCHKIS & WILEY 266,800 sh (+270.56%)
Paul Tudor Jones 13,100 sh (+92.65%)
Jim Simons Sold Out
Vanguard Health Care Fund 1,587,000 sh (-11.19%)
Joel Greenblatt 280,089 sh (-15.82%)
Steven Cohen 7,888 sh (-62.21%)
» More
Q4 2012

UTHR Guru Trades in Q4 2012

David Dreman 57,025 sh (New)
Steven Cohen 13,453 sh (+70.55%)
Paul Tudor Jones 15,200 sh (+16.03%)
Joel Greenblatt 289,442 sh (+3.34%)
John Hussman 500,000 sh (unchged)
HOTCHKIS & WILEY Sold Out
Vanguard Health Care Fund 1,487,000 sh (-6.3%)
» More
Q1 2013

UTHR Guru Trades in Q1 2013

Jim Simons 323,175 sh (New)
Paul Tudor Jones 16,700 sh (+9.87%)
Joel Greenblatt 295,921 sh (+2.24%)
Steven Cohen Sold Out
David Dreman 55,625 sh (-2.46%)
John Hussman 468,000 sh (-6.4%)
Vanguard Health Care Fund 1,320,000 sh (-11.23%)
» More
» Details

Insider Trades

Latest Guru Trades with UTHR

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
David Dreman 2012-12-31 New Buy0.09%$44.99 - $58.91 $ 68.4731%57025
John Hussman 2012-09-30 New Buy0.67%$49.73 - $58.2 $ 68.4726%500000
Joel Greenblatt 2012-06-30 Add 101.59%0.6%$41.19 - $49.51 $ 68.4755%332744
Richard Perry 2012-06-30 Sold Out 0.04%$41.19 - $49.51 $ 68.4755%0
Joel Greenblatt 2012-03-31 Add 82.68%0.31%$45.54 - $50.99 $ 68.4752%165063
Richard Perry 2012-03-31 New Buy0.04%$45.54 - $50.99 $ 68.4752%15300
Joel Greenblatt 2011-12-31 Add 38.75%0.15%$37.21 - $47.54 $ 68.4765%90355
Joel Greenblatt 2011-09-30 Add 274.82%0.29%$37.47 - $57.38 $ 68.4741%65122
Vanguard Health Care Fund 2011-09-30 Add 77.9%0.16%$37.47 - $57.38 $ 68.4741%1787000
Michael Price 2011-09-30 Sold Out 0.1%$37.47 - $57.38 $ 68.4741%0
George Soros 2011-09-30 Sold Out 0.0776%$37.47 - $57.38 $ 68.4741%0
Michael Price 2011-06-30 Reduce -82.59%0.59%$53.49 - $70.7 $ 68.478%12500
Vanguard Health Care Fund 2011-06-30 Add 183.36%0.18%$53.49 - $70.7 $ 68.478%1004500
Joel Greenblatt 2011-06-30 New Buy0.13%$53.49 - $70.7 $ 68.478%17374
Michael Price 2011-03-31 Reduce -24.97%0.24%$63.22 - $69.54 $ 68.472%71800
George Soros 2011-03-31 Add 1213.41%0.08%$63.22 - $69.54 $ 68.472%107700
Joel Greenblatt 2011-03-31 Sold Out $63.22 - $69.54 $ 68.472%0
George Soros 2010-12-31 Reduce -95.62%0.22%$54.26 - $64.24 $ 68.4714%8200
Joel Greenblatt 2010-12-31 New Buy0.13%$54.26 - $64.24 $ 68.4714%6216
Michael Price 2010-09-30 Add 38.29%0.3%$46.22 - $56.07 $ 68.4737%95700
George Soros 2010-09-30 Add 1447.93%0.15%$46.22 - $56.07 $ 68.4737%187300
Michael Price 2010-06-30 Add 147.14%0.44%$49 - $58.49 $ 68.4727%69200
Vanguard Health Care Fund 2010-06-30 Add 45.05%0.03%$49 - $58.49 $ 68.4727%322000
George Soros 2010-06-30 New Buy0.02%$49 - $58.49 $ 68.4727%12100
Michael Price 2010-03-31 Add 180%0.21%$52.43 - $61.46 $ 68.4720%28000
George Soros 2010-03-31 Sold Out 0.01%$52.43 - $61.46 $ 68.4720%0
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about United Therapeutics Corporation

Weekly CEO Buys Highlight: UTHR, DNR, RICK, PERF
January 7, 2013
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: UTHR, LUB, ACMP, GBL, CBK
December 30, 2012
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: UTHR, PMC, ABR, AIR, SCHS
June 23, 2012
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Utd Therapeutic (UTHR): CEO Martine A Rothblatt Bought 20,858 Shares Read more...
Weekly CEO Buys Highlight: UTHR, TAT, PMC, BRCD, ENDP
June 16, 2012
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
CEO of Utd Therapeutic Martine Rothblatt Bought 13,649 Shares
June 14, 2012
CEO of Utd Therapeutic (UTHR) Martine A. Rothblatt bought 13,649 shares on June 13, 2012, at an average price of $43.6. The total transaction amount is $595,096. Utd Therapeutic is a biotechnology company focused on combating cardiovascular, inflammatory and infectious diseases with unique therapeutic products. Utd Therapeutic has a market cap of $2.32 billion; its shares were traded at around $45.42 with a P/E ratio of 9.8 and P/S ratio of 3.1. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 12.10
UTHR's P/E(ttm) is ranked higher than
82% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 20.85 vs. UTHR: 12.10 )
UTHR' s 10-Year P/E(ttm) Range
Min: 8.83   Max: 216.7
Current: 12.1
8.83
216.7
P/B 3.20
UTHR's P/B is ranked higher than
63% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. UTHR: 3.20 )
UTHR' s 10-Year P/B Range
Min: 0.88   Max: 18.62
Current: 3.2
0.88
18.62
P/S 3.77
UTHR's P/S is ranked higher than
71% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. UTHR: 3.77 )
UTHR' s 10-Year P/S Range
Min: 2.83   Max: 2321.9
Current: 3.77
2.83
2321.9
PFCF 11.60
UTHR's PFCF is ranked higher than
77% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 24.02 vs. UTHR: 11.60 )
UTHR' s 10-Year PFCF Range
Min: 10.28   Max: 1199.4
Current: 11.6
10.28
1199.4
EV-to-EBIT 7.2
UTHR's EV-to-EBIT is ranked higher than
85% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. UTHR: 7.2 )
UTHR' s 10-Year EV-to-EBIT Range
Min: 5.5   Max: 363.2
Current: 7.2
5.5
363.2
Shiller P/E 33.2
UTHR's Shiller P/E is ranked higher than
81% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. UTHR: 33.2 )
UTHR' s 10-Year Shiller P/E Range
Min: 25.28   Max: 138.81
Current: 33.2
25.28
138.81

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 32.8
UTHR's Price/Net Current Asset Value is ranked higher than
70% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. UTHR: 32.8 )
UTHR' s 10-Year Price/Net Current Asset Value Range
Min: 25.3   Max: 80.4
Current: 32.8
25.3
80.4
Price/Tangible Book 3.2
UTHR's Price/Tangible Book is ranked higher than
57% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. UTHR: 3.2 )
UTHR' s 10-Year Price/Tangible Book Range
Min: 1.2   Max: 7.6
Current: 3.2
1.2
7.6
Price/DCF (Projected) 1.6
UTHR's Price/DCF (Projected) is ranked higher than
91% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. UTHR: 1.6 )
UTHR' s 10-Year Price/DCF (Projected) Range
Min: 1.4   Max: 23.8
Current: 1.6
1.4
23.8
Price/Median PS Value 0.4
UTHR's Price/Median PS Value is ranked higher than
53% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. UTHR: 0.4 )
UTHR' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 16.4
Current: 0.4
0.3
16.4
Price/Graham Number 1.3
UTHR's Price/Graham Number is ranked higher than
83% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. UTHR: 1.3 )
UTHR' s 10-Year Price/Graham Number Range
Min: 1.1   Max: 6.1
Current: 1.3
1.1
6.1
Earnings Yield (Greenblatt) 13.80
UTHR's Earnings Yield (Greenblatt) is ranked higher than
87% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. UTHR: 13.80 )
UTHR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 18
Current: 13.8
0.3
18
Forward Rate of Return (Yacktman) 0.9
UTHR's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -4.65 vs. UTHR: 0.9 )
UTHR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4.7   Max: 1.5
Current: 0.9
-4.7
1.5

Business Description

United Therapeutics Corporation was incorporated in Delaware in June 1996. The Company is a biotechnology company, which is focused on the development and commercialization of products to address the medical needs of patients with chronic and life-threatening conditions. The Company operates two business segments: pharmaceuticals and telemedicine. The pharmaceutical segment includes all activities associated with the research, development, manufacturing and commercialization of its therapeutic products. The telemedicine segment includes all activities associated with the development and manufacturing of patient cardiac monitoring products and services. Its therapeutic products and product candidates include: Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor, Monoclonal Antibodies (MAbs),Glycobiology Antiviral Agents, and Cell-Based Therapy. Prostacyclin analogues are stable synthetic forms of prostacyclin, an important molecule produced by the body that has powerful effects on blood vessel health and function. Its lead product is Remodulin (treprostinil) Injection (Remodulin) to be administered subcutaneously or intravenously for the treatment of pulmonary arterial hypertension (PAH). PDE-5 inhibitors act to inhibit the degradation of cyclic guanosine monophosphate (cGMP) in cells. cGMP is activated by nitric oxide (NO) to effect relaxation of vascular smooth muscle. Its PDE-5 inhibitor product is Adcirca (tadalafil) tablets (Adcirca), a once-daily oral therapy for the treatment of PAH. MAbs act by targeting tumor-associated antigens on cancer cells to activate a patient's immune system against the cancer cells. The Company is developing the antibody Ch14.18 MAb for the treatment of neuroblastoma, under an agreement with the National Cancer Institute. Glycobiology antiviral agents are a novel class of small, sugar-like molecules that have shown pre-clinical indications of efficacy against a broad range of viruses. The Company generates revenues mainly from the sale of Remodulin, Tyvaso and Adcirca. The Company competes with the developers, manufacturers and distributors of all of these products for customers, funding, access to licenses, personnel, third-party collaborators, product development and commercialization.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:UTH.Germany
ยป More Articles for UTHR

Headlines

Articles On GuruFocus.com
Super-Fast Growing Mid-Cap Growth Stocks with Explosive Returns May 09 2013 
5 Fast-Growing Small-Cap Stocks to Watch Mar 26 2013 
Weekly CEO Buys Highlight: UTHR, DNR, RICK, PERF Jan 07 2013 
Weekly CEO Buys Highlight: UTHR, LUB, ACMP, GBL, CBK Dec 30 2012 
Weekly CEO Buys Highlight: NGL, BRKR, UTHR, KTOS, GBL Dec 24 2012 
Weekly CEO Buys Highlight: UTHR, PMC, ABR, AIR, SCHS Jun 23 2012 
Weekly CEO Buys Highlight: UTHR, TAT, PMC, BRCD, ENDP Jun 16 2012 
CEO of Utd Therapeutic Martine Rothblatt Bought 13,649 Shares Jun 14 2012 
Weekly CEO Buys Highlight: CKH, UTHR, DRL, VAC, DENN Dec 23 2011 
United Therapeutics (UTHR) CEO Martine A. Rothblatt buys 12,701 Shares Dec 19 2011 

More From Our Partners
Bayer Files Riociguat in Japan - Analyst Blog May 21 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial